France's Cellectis wins U.S patents for gene editing technology

PARIS (Reuters) - The United States has granted French cell therapy group Cellectis two patents to deploy a technology known as CRISPR in T cells, which play a key role in the immune response to cancer, the company said on Tuesday.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news